CTLA4 and cancer: For instance, CPI therapy against programmed cell death protein 1 (PD1), or cytotoxic T-lymphocyte associated protein 4 (CTLA4) targets predominantly T cells [15–17], while inhibition of the CD47-signal-regulatory protein α (SIRPα) axis focuses on the interactions between cancer cells and macrophages [18].